Coeptis Therapeutics (NASDAQ:ZSQR) Shares Gap Down – Here’s Why

Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR)’s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $14.71, but opened at $13.11. Coeptis Therapeutics shares last traded at $13.15, with a volume of 5,389 shares trading hands.

Wall Street Analyst Weigh In

Separately, Wall Street Zen lowered shares of Coeptis Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Coeptis Therapeutics presently has an average rating of “Sell”.

Coeptis Therapeutics Stock Up 2.7%

The company has a current ratio of 3.25, a quick ratio of 3.25 and a debt-to-equity ratio of 0.01. The firm’s fifty day moving average price is $12.35 and its 200-day moving average price is $12.81. The company has a market cap of $706.65 million, a price-to-earnings ratio of -5.45 and a beta of -0.22.

Coeptis Therapeutics (NASDAQ:ZSQR) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.65) EPS for the quarter. The business had revenue of $0.11 million for the quarter. Coeptis Therapeutics had a negative return on equity of 92.29% and a negative net margin of 810.04%.

Institutional Investors Weigh In On Coeptis Therapeutics

A number of hedge funds have recently modified their holdings of the business. Marshall Wace LLP acquired a new position in shares of Coeptis Therapeutics in the 4th quarter valued at approximately $259,000. Yorkville Advisors Global LP bought a new stake in Coeptis Therapeutics during the 3rd quarter worth approximately $140,000. State Street Corp raised its holdings in Coeptis Therapeutics by 35.0% during the 4th quarter. State Street Corp now owns 26,830 shares of the company’s stock worth $382,000 after buying an additional 6,962 shares during the period. Geode Capital Management LLC raised its holdings in Coeptis Therapeutics by 12.6% during the 4th quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock worth $600,000 after buying an additional 4,721 shares during the period. Finally, Steward Partners Investment Advisory LLC lifted its stake in Coeptis Therapeutics by 100.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock valued at $71,000 after buying an additional 2,500 shares in the last quarter. Institutional investors and hedge funds own 13.88% of the company’s stock.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.